Business Wire

MSD Animal Health Extends Commitment to Fighting Rabies in the World’s Most At-Risk Regions

Jaa

Today marks the midway milestone for World Rabies Day, when the Global Alliance for Rabies Control, together with health organizations from around the world, set a goal of eliminating human rabies transmitted by dogs by 2030. MSD Animal Health (known as Merck Animal Health in the United States and Canada) is pleased to announce our continued support in the fight against rabies through the donation of NOBIVAC® Rabies vaccine and other resources to the Afya Serengeti Project and Mission Rabies, organizations working to eliminate this disease in the world’s most at-risk regions.

Rabies, a neglected disease of vulnerable populations, is nearly 100 percent fatal but also nearly 100 percent preventable through canine vaccination. Yet midway to the global health community’s deadline for eliminating canine-mediated rabies, Africa and India still bear the highest burden of total annual rabies deaths.i Countries with the highest fatalities from rabies are India, Democratic Republic of the Congo, Ethiopia, China and Myanmar.ii

“Each year, an estimated 60,000 people die from rabies, with 40 percent of those deaths occurring in children under the age of fifteen,” said Ingrid Deuzeman, global marketing director, MSD Animal Health. “We are resolved to continue our collaboration with the Afya Serengeti Project, which we’ve been committed to for more than 15 years, and with Mission Rabies, in support of the global health community goal to eliminate rabies.”

Progress in the Fight Against Rabies

In more than 20 participating countries, when pet owners and veterinarians choose NOBIVAC vaccines, it allows MSD Animal Health to donate rabies vaccine to Mission Rabies and the Afya Serengeti Project.

“Mission Rabies launched at the end of 2013 and to date we’ve delivered the NOBIVAC Rabies vaccine to 700,000 street dogs in some of the world’s worst rabies hotspots. Our flagship projects are delivering amazing results with no human rabies cases having been reported in the Indian city of Ranchi, the State of Goa or the city of Blantyre in Malawi so far this year. It’s incredible considering just a few years ago, a hospital in Blantyre (the Queen Elizabeth Central Hospital) was reporting the highest incidence of child rabies deaths from any single institution in the whole of Africa,” said Luke Gamble, founder, Mission Rabies. “We are all driven to power Mission Rabies forward and without the support of MSD Animal Health NOBIVAC Rabies vaccine, we couldn’t do what we do. The vaccine is saving lives amongst some of the poorest and most vulnerable people in the world and it’s a privilege to be a part of this project with everyone.”

“The human toll of rabies is needless and tragic. However, over the past 20 years, we have shown that vaccination programs can reach enough dogs to eliminate rabies anywhere in the world,” said Professor Sarah Cleaveland, founder, Afya Serengeti Project. “With continued support from MSD Animal Health and other collaborators, I believe we have the vaccine and the tools to achieve zero human deaths from dog rabies by 2030.”

For more information, visit www.afya.org, www.missionrabies.com and http://rabiesalliance.org/world-rabies-day. Please see Prescribing Information for NOBIVAC® Vaccines at www.nobivac.com.

Eliminating Rabies in India and Africa

Since 2013, Mission Rabies has set a goal to vaccinate dogs across rabies hotspots in India, where over a third of all human rabies deaths occur.iii Based on the program’s success in India, Mission Rabies has expanded its offering to Africa.

Mission Rabies does more than just vaccinate hundreds of thousands of dogs against rabies each year. They go to schools and educate children in these communities, informing them of the seriousness of the disease. Children are the most affected by rabies because they play with dogs and don’t understand how deadly rabies can be.

Using a fast-paced team of veterinarians and volunteers, Mission Rabies has so far vaccinated more than 505,000 dogs, trained 80 veterinarians, and educated more than 1,200,000 children about the risk of rabies.

Saving Lives in the Serengeti

The Afya Serengeti Project has prevented thousands of deaths in the Serengeti through the widespread vaccination of domestic dogs. Since the start of the program, the incidence of human rabies, rabies in dogs and rabid dog bites has dropped to an all-time low.iv Each year, over 600 dog rabies cases have been prevented and 23 human lives saved. The effective control of rabies through dog vaccination has also had benefits for wildlife, including endangered African wild dogs, which have become re-established in the Serengeti National Park for the first time since the population disappeared as a result of rabies outbreaks in the early 1990s. Understanding the importance of providing vaccinations to other at-risk areas, the Afya Project has extended to Kenya, Bangalore and the Pune region of India.

About MSD Animal Health

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

###

i World Health Organization. Rabies Fact Sheet: Epidemiology. Accessed June 23, 2017 at http://www.who.int/rabies/epidemiology/en/.
ii Hampson K, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9(4). Accessed June 23, 2017 at http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003709#pntd.0003709.s002.
iii World Health Organization. Bulletin of the World Health Organization. “India’s ongoing war against rabies.” Bulletin of the World Health Organization. Volume 87, Number 12, December 2009, 885-964. Accessed June 17, 2015 via http://www.who.int/bulletin/volumes/87/12/09-021209/en/.
iv Kaare M, Lembo T, Hampson K, et al. Rabies control in rural Africa: evaluating strategies for effective domestic dog vaccination. Vaccine. 2009;27(1):152–160.

Contact information

Media Contact:
MSD Animal Health
Logan Rizzo, +1-973-937-5590
Pam Eisele, +1-267-305-3558

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

UniPrint Infinity Now Available in Epic App Orchard14.12.2017 22:07Tiedote

UniPrint.net announced today that UniPrint Infinity software is now available in the Epic App Orchard Marketplace. Users can now take advantage of UniPrint Infinity’s secure release print suite which works with any printer, any device, and in any computing environment. UniPrint Infinity’s PDF-based Healthcare Printing Suite provides industry standard 256-bit data encryption and compression, high availability, archiving, and “follow-the-user” printing, resulting in increased security and compliance in addition to reduced print costs. Implementation of UniPrint Infinity is proven to reduce wait times and help desk calls. By improving workflows for doctors, nurses, and other healthcare providers, UniPrint Infinity allows healthcare staff to focus their attention on their most important task: providing better patient care. “Building upon our recent Imprivata SSO integrati

FINEOS Announces Three New Customers in the Cloud14.12.2017 18:57Tiedote

FINEOS Corporation, the market leading provider of core systems for Life, Accident and Health (LA&H) insurance, today announced three new customers who have acquired FINEOS as a cloud service. The three new FINEOS customers, based in the US, Sweden and Canada respectively, have licenced FINEOS for their group insurance core processing needs. FINEOS is partnering with Amazon Web Services (AWS), the world’s largest IaaS cloud provider, to deliver the FINEOS Software as a Service (SaaS) offering. FINEOS Insurance Cloud is designed for the specific compliance and security needs of the LA&H industry. With simple subscription pricing, a FastTrack implementation approach, 24 x 7 support and continuous upgrades, the FINEOS Insurance Cloud is the way forward for LA&H insurance core systems. Speaking about the cloud, Gartner has said “By 2020, a Corporate ‘

UniPrint Infinity Now Available in Epic App Orchard14.12.2017 18:52Tiedote

UniPrint.net announced today that UniPrint Infinity software is now available in the Epic App Orchard Marketplace. Users can now take advantage of UniPrint Infinity’s secure release print suite which works with any printer, any device, and in any computing environment. UniPrint Infinity’s PDF-based Healthcare Printing Suite provides industry standard 256-bit data encryption and compression, high availability, archiving, and “follow-the-user” printing, resulting in increased security and compliance in addition to reduced print costs. Implementation of UniPrint Infinity is proven to reduce wait times and help desk calls. By improving workflows for doctors, nurses, and other healthcare providers, UniPrint Infinity allows healthcare staff to focus their attention on their most important task: providing better patient care. “Building upon our recent Imprivata SSO integrati

Abdullah bin Zayed Honors Winners of the Al Hassan Bin Ali Award 2017 as Part of the Fourth Annual Forum for Promoting Peace in Muslim Societies14.12.2017 18:19Tiedote

His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation, hosted a ceremony to honor the ‘Egyptian Family House’, winner of the Imam Al Hassan bin Ali Award 2017, represented by Dr. Mahmoud Hamdi Zaqzouq, Secretary General, and His Eminence Anba Ermia, Assistant Secretary General. Also present were H.E Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and H.E Shaykh Abdallah Bin Bayyah, President of the Forum for Promoting Peace in Muslim Societies. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171214005883/en/ Left to right: H.E Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance, H.H Sheikh Abdullah bin Zayed Al Nahyan, Minister of Foreign Affairs and International Cooperation, H.E Shaykh Abdallah Bin Bayyah, President of the Forum for Promoting Peace in Muslim

Kymeta Announces Commercial Availability of KĀLO™ Mobile Internet Access Services14.12.2017 18:00Tiedote

Kymeta—the communications company making good on the promise of global, mobile connectivity—and Intelsat S.A. (NYSE:I)—operator of the world’s first globalized network—have announced that Kymeta KĀLO internet access is now available with broad initial geographic coverage. Kymeta is redefining how satellite services are purchased with KĀLO internet services, and making mobile communications as easy to buy as a mobile phone plan. KĀLO internet services, powered by the IntelsatOne® Flex network, deliver broad connectivity when paired with the world’s only commercially available flat panel, electronically-steered satellite terminals from Kymeta as well as other satellite terminal solutions. Kymeta™ KyWay™ terminals and mTennau7 antenna subsystem modules open new markets for the satellite industry and allow organizations that require high-bandwidth mobile internet access to do busine

BioVectra and Keryx Biopharmaceuticals Enter Agreement for Ferric Citrate Production Expansion14.12.2017 16:47Tiedote

BioVectra Inc., an innovative global contract development and manufacturing organization (CDMO), today announced a long-term supply agreement with Keryx Biopharmaceuticals, Inc., to manufacture Ferric Citrate, the active pharmaceutical ingredient (API) in Auryxia® tablets, a medicine approved for the treatment of two common complications of chronic kidney disease. BioVectra Inc. brings over 45 years of contract development and manufacturing experience to the partnership, including working with Keryx to manufacture Ferric Citrate API since 2003. BioVectra will prepare for the anticipated growth in the long-term Ferric Citrate API supply needs by expanding production capacity at their headquarters facility in Charlottetown, PEI, Canada. “This partnership is a pivotal step in our journey as BioVectra. It is a shining example of the innovation, talent and determination we have

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme